PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Scott H. Davis who wrote (403)	8/24/1999 12:57:00 AM
From: Miljenko Zuanic	Read Replies (1) of 626

<<On partnered vs non-partnered. You're probably right, but there is the possibility they are intentionally going it alone to reach for bigger profit down stream, except TTP,s not too strong financially. >> Cancer clinical trials with antibody based vaccines are long and expensive. This agents are usually added to CHOP or for post-CHOP therapy. TTP does not have expertise or finance for this type of work. They need partner, but I doubt that anyone will pull trigger until preliminary PII data for CeaVac are known. So, will see in next 12-16 months what will emerge, if anything. Regards the Spheramine, Emory is very reputable institution for basic research. I will not be surprised if TTP anounce partner before IND file, but I am not holding my breath. Ilo and Pivanex are sufficient for my safe investment. Miljenko PS. I like VICL and support from MRK. However, I do not have adequate DD and knowledge about naked DNA vaccines to comment in depth. I guess VICL tread is pretty good. At least the best expert here on SI do regularly post about their technology.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next